91 results
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
21 May 19
Second generationmicroRNA-29 replacement shows efficacy in blunting fibrosis in the bleomycin model of pulmonary fibrosis when dosed systemically
7:15am
the studies demonstrated a down-regulation of certainpro-fibrotic genes that were previously established as targets ofmicroRNA-29. These effects extended … to downstream targets involved in thepro-fibrotic response, including connective tissue growth factor(CTGF). The downregulation of these mechanistic
10-Q
2014 Q2
EX-10.1
VRDN
Viridian Therapeutics Inc
14 Aug 14
Quarterly report
12:00am
Measures and objective performance targets to be attained relative to those Performance Measures, all as determined by the Administrator. Performance … targets may include minimum, maximum, intermediate and target levels of performance, with the size of the performance-based stock award or the lapse
8-K
VRDN
Viridian Therapeutics Inc
8 Feb 19
Departure of Directors or Certain Officers
4:18pm
of the Plan Related Agreements that we have filed with the SEC.
2019 Base Salary and Bonus Targets
On February 6, 2019, the Compensation Committee … . Levy
Chief Business Officer
Paul D. Rubin, M.D.
Executive Vice President, Research and Development
(1) Bonus Targets listed as percentage of 2019 Base
8-K
VRDN
Viridian Therapeutics Inc
7 Aug 19
Miragen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
4:00pm
-targeting therapeutics for certain microRNA targets in the cardiovascular field. In 2017, the Servier Agreement was amended to remove all existing … targets and add one new target (miR-92). Under the Servier Agreement, Servier’s rights to each named target were limited to therapeutics in the field
8-K
4u4oart4 grb
19 Feb 20
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.2
empts31a rzt79
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-99.1
xsii3pmqib8
25 Mar 21
Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
4:06pm
8-K
x939iyq ir
30 Oct 23
Entry into a Material Definitive Agreement
8:35am
8-K
EX-99.1
z6uibu v3cxss1i52
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-99.1
jnrrhp0106zmd
13 Nov 23
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
mg3w40fh
8 May 24
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
7:09am